SB 223412

06/01/2008 - "Taken together, these data demonstrate that talnetant is a selective, competitive, brain-penetrant NK3 receptor antagonist with the ability to modulate mesolimbic and mesocortical dopaminergic neurotransmission and hence support its potential therapeutic utility in the treatment of schizophrenia."
11/01/2014 - "Phase II clinical trials in schizophrenia with two selective NK3 antagonists (osanetant and talnetant) have demonstrated significant improvement in positive symptoms. "
02/01/2011 - "Clinical results of osanetant and talnetant (selective-NK₃ antagonists) indicate that blocking the NK₃ receptor could be beneficial for the treatment of schizophrenia. "
01/01/2010 - "Central Nervous System (CNS) effects of talnetant, an NK-3 antagonist in development for schizophrenia, were compared to those of haloperidol and placebo. "
07/01/2005 - "Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. "

05/01/2011 - "Preclinical and Phase II clinical results of osanetant and talnetant in schizophrenic patients have indicated that NK(3) antagonists may provide significant improvement of the positive symptoms and cognitive impairment associated with this disorder. "

10/01/1997 - "In addition, NK3 receptor agonist-induced miosis in conscious rabbits is a good in vivo correlate of the in vitro rabbit iris sphincter muscle preparation and appears to be a useful model for characterizing the pharmacodynamic profile and efficacy of structurally distinct NK3 receptor antagonists, such as SB 222200, SB 223412, SB 218795 and SR 142801."

04/01/2004 - "Studies with talnetant and other selective NK3 receptor antagonists are, therefore, revealing an exciting and novel pathway by which pathological changes in intestinal motility and nociception can be induced, suggesting a role for NK3 receptor antagonism in irritable bowel syndrome."
07/01/2005 - "Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. "
08/01/2006 - "Other clinical candidates (for central nervous system disorders: osanetant, talnetant and saredutant; for irritable bowel syndrome: nepadutant and saredutant) are in advanced clinical phase. "

08/01/2003 - "This study was designed to determine whether NK3 receptor antagonists crossing (talnetant) or not (SB-235375) the blood-brain barrier reduce the nociceptive response to colo-rectal distension (CRD) and whether NK3 antagonism reduces inflammation- or stress-induced hypersensitivity to rectal distension. "
08/01/2003 - "Talnetant (10 mg kg-1, p.o.) abolished the increase observed for 0.8 and 1.2 mL. These results indicate that peripheral NK3 receptor antagonism reduced nociception associated with CRD and hypersensitivity induced by stress but not inflammation."